This partnership targets gastrointestinal cancers with significant unmet medical needs, combining two powerhouse platforms: #48Hour Discovery’s rapid peptide discovery engine. #AdvanCell’s scalable 212Pb platform and clinical expertise. By integrating secure isotope supply with precision-engineered peptides, this program is set for a rapid path to the clinic in 2027. Following the recent success of AdvanCell’s lead program (ADVC001), this expansion reinforces the potential of Alpha Therapy to transform outcomes for cancer patients globally. #BCIC #Bostoncapitalinvestmentclub #Radiopharmaceuticals #AlphaTherapy #Oncology
Accelerating Targeted Alpha Therapies: AdvanCell & 48Hour Discovery Join Forces 🔬
Big news in the radiopharmaceutical space! #AdvanCell has officially entered a Collaboration and Exclusive Licensing Agreement with #48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic.
